Gyre Therapeutics, Inc. GYRE Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $37.07M+214% | $11.81M-64.7% | $33.51M+33.1% | $25.18M-43.2% | ||
| $15.36M+3.3% | $14.86M— | —— | —— | ||
| $101.73M+39.1% | $73.16M+258% | $20.41M+31.1% | $15.56M+163% | ||
| $35.76M+53.6% | $23.29M+757% | $2.72M-59.9% | $6.78M— | ||
| $2.83M+7.7% | $2.63M+151% | $1.05M-32.1% | $1.54M-45.1% | ||
| $102.37M+58.0% | $64.79M+13.2% | $57.22M+15.2% | $49.65M-3.5% | ||
| $23.6M-1.2% | $23.88M+2.5% | $23.29M+31.5% | $17.71M+1,726% | ||
| $4.73M+1,632% | $273K0.0% | $273K-8.1% | $297K— | ||
| $6.87M+22.3% | $5.62M+19.7% | $4.7M+15.0% | $4.08M— | ||
| $5.05M+66.6% | $3.03M+205% | $995K-70.7% | $3.39M+619% | ||
| $166.13M+32.5% | $125.41M+7.6% | $116.54M+37.5% | $84.75M+52.3% | ||
| $124K+14.8% | $108K-69.6% | $355K+191% | $122K-98.1% | ||
| $227K0.0% | $227K-83.4% | $1.37M+1,060% | $118K-97.1% | ||
| $14K-77.0% | $61K+56.4% | $39K-66.9% | $118K-48.7% | ||
| $636K-10.8% | $713K+240% | $210K-57.3% | $492K-75.1% | ||
| $2.94M+3.9% | $2.83M-44.0% | $5.05M+141% | $2.1M— | ||
| $18.29M-6.3% | $19.52M-2.6% | $20.05M+63.8% | $12.24M-13.6% | ||
| $303K-65.8% | $885K+345% | $199K+64.5% | $121K-70.3% | ||
| $939K-41.2% | $1.6M+291% | $409K+976% | $38K-98.4% | ||
| $1.45M+20,586% | $7K-85.7% | $49K-10.9% | $55K— | ||
| $23.85M-11.7% | $27M-29.1% | $38.07M+204% | $12.54M-14.0% | ||
| $91K+5.8% | $86K+11.7% | $77K+20.3% | $64K+106% | ||
| $172.05M+26.3% | $136.19M+99.7% | $68.18M+108% | $32.8M-92.6% | ||
| -$68.43M+6.8% | -$73.45M+14.1% | -$85.54M-1,257% | $7.4M+102% | ||
| -$779K+70.0% | -$2.6M-58.0% | -$1.64M-319% | -$392K— | ||
| $36.25M+3.3% | $35.08M+17.8% | $29.78M+0.3% | $29.7M— | ||
| $106.03M+67.5% | $63.32M+500% | -$15.83M-137% | $42.52M+3.5% | ||
| $166.13M+32.5% | $125.41M+7.6% | $116.54M+37.5% | $84.75M+52.3% | ||
| $5.64M+28.9% | $4.37M+1,024% | $389K— | —— | ||
| $5.05M+66.6% | $3.03M+205% | $995K-70.7% | $3.39M+619% | ||
| $6.87M+22.3% | $5.62M+19.7% | $4.7M+15.0% | $4.08M— | ||
| $4.73M+1,632% | $273K0.0% | $273K-8.1% | $297K— | ||
| $23.52M-4.3% | $24.57M+4.9% | $23.43M+217% | $7.39M— | ||
| $5.05M+66.6% | $3.03M+205% | $995K-70.7% | $3.39M+619% | ||
| $15.36M+3.3% | $14.86M— | —— | —— | ||
| $5.05M+66.6% | $3.03M+205% | $995K-70.7% | $3.39M+619% | ||
| $2.94M+3.9% | $2.83M-44.0% | $5.05M+141% | $2.1M— | ||
| $227K0.0% | $227K-83.4% | $1.37M+1,060% | $118K— | ||
| $2.96M-47.8% | $5.67M-55.8% | $12.84M— | —— | ||
| $14.36M+35.3% | $10.62M-11.1% | $11.94M+28.8% | $9.26M— | ||
| $852K-8.2% | $928K+336% | $213K+80.5% | $118K— | ||
| $939K-41.2% | $1.6M+291% | $409K+976% | $38K-98.4% | ||
| $91K+5.8% | $86K+11.7% | $77K+20.3% | $64K+106% | ||
| $3.1M0.0% | $3.1M0.0% | $3.1M+16.5% | $2.66M— | ||
| $2.96M-47.8% | $5.67M-55.8% | $12.84M— | —— | ||
| $36.25M+3.3% | $35.08M+17.8% | $29.78M+0.3% | $29.7M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Gyre Therapeutics, Inc.'s total assets?
- Gyre Therapeutics, Inc. (GYRE) holds $162.0M in total assets, up 24.8% year over year.
- How much debt does Gyre Therapeutics, Inc. have?
- Gyre Therapeutics, Inc. carries $823.0K in total debt against $101.3M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Gyre Therapeutics, Inc. have?
- Gyre Therapeutics, Inc. holds $37.5M in cash and equivalents.
- Can Gyre Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 4.64 — current assets exceed current liabilities.
- Where does Gyre Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
